SCHEMBL7945674

SCHEMBL7945674

COc1ccc(C(=O)Nc2ccc(F)c(CNc3cccnc3N)c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.61
AURKB Q96GD4 2/20 0.61
RAB9A P51151 5/20 0.53
NPC1 O15118 3/20 0.53
HDAC1 Q13547 7/20 0.52
HDAC3 O15379 3/20 0.51
HDAC2 Q92769 3/20 0.51
HDAC4 P56524 2/20 0.51
HDAC7 Q8WUI4 2/20 0.51
HDAC10 Q969S8 2/20 0.51
HDAC11 Q96DB2 2/20 0.51
HDAC8 Q9BY41 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
HDAC9 Q9UKV0 2/20 0.51
HDAC5 Q9UQL6 2/20 0.51
EPHA2 P29317 1/20 0.51
BACE1 P56817 3/20 0.49
NCOR2 Q9Y618 2/20 0.48
PPARG P37231 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7944850 0.89 BACE1 (0.56) AURKAAURKBBACE1
SCHEMBL7943486 0.88 NPC1 (0.48) AURKAAURKBRAB9ANPC1HDAC1
SCHEMBL7934095 0.87 PTGS1 (0.49) AURKAAURKBHDAC1
SCHEMBL7935460 0.86 BACE1 (0.49) AURKAAURKBBACE1
SCHEMBL7946412 0.85 BACE1 (0.50) AURKAAURKBBACE1
SCHEMBL7941739 0.85 BACE1 (0.50) AURKAAURKBBACE1
SCHEMBL7945106 0.84 AURKA (0.47) AURKAAURKBRAB9ANPC1BACE1
SCHEMBL7941383 0.83 RAB9A (0.53) AURKAAURKBRAB9ANPC1HDAC1
SCHEMBL7940344 0.83 BACE1 (0.69) AURKAAURKBRAB9ANPC1HDAC1
SCHEMBL7942889 0.83 NPC1 (0.54) AURKAAURKBRAB9ANPC1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 AURKA 3552/4885AURKB 2842/4885RAB9A 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.